close
References
  1. Jensen MD, Ryan DH, Apovian CM, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985-3023.
  2. World Health Organization. The Asia-Pacific perspective: redefining obesity and its treatment. February 2000. https://iris.wpro.who.int/handle/10665.1/5379. Accessed August 11, 2020.
  3. Padwal RS, Pajewski NM, Allison DB, Sharma AM. Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. CMAJ. 2011;183(14):E1059-E1066.
  4. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362.
  5. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376(3):254-266.
  6. Bray MS, Loos RJ, McCaffery JM, et al; Conference Working Group. NIH working group report-using genomic information to guide weight management: from universal to precision treatment. Obesity (Silver Spring). 2016;24(1):14-22.
  7. van der Valk ES, van den Akker ELT, Savas M, et al. A comprehensive diagnostic approach to detect underlying causes of obesity in adults. Obes Rev. 2019;20(6):795-804.
  8. Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue an endocrine organ. Arch Med Sci. 2013;9(2):191-200.
  9. Berthoud HR, Munzberg H, Morrison CD. Blaming the brain for obesity: integration of hedonic and homeostatic mechanisms. Gastroenterology. 2017;152(7):1728-1738.
  10. Dietrich MO, Horvath TL. Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. Nat Rev Drug Discov. 2012;11(9):675-691.
  11. Lean ME, Malkova D. Altered gut and adipose tissue hormones in overweight and obese individuals: cause or consequence? Int J Obes (Lond). 2016;40(4):622-632.
  12. Ravussin E, Ryan DH. Energy expenditure and weight control: is the biggest loser the best loser? Obesity (Silver Spring). 2016;24(8):1607-1608.
  13. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-1604.
  14. Dietz WH, Gallagher C. A proposed standard of obesity care for all providers and payers. Obesity. 2019;27(7):1059-1062.
  15. Dietz WH, Belay B, Bradley D, et al. A model framework that integrates community and clinical systems for the prevention and management of obesity and other chronic diseases. January 13, 2017. Washington, DC: National Academy of Medicine. https://nam.edu/a-model-framework-that-integrates-community-and-clinical-systems-for-the-prevention-and-management-of-obesity-and-other-chronic-diseases. Accessed August 11, 2020.
  16. Kyle TK, Puhl RM. Putting people first in obesity. Obesity (Silver Spring). 2014;22(5):1211.
  17. Puhl RM, Brownell KD. Confronting and coping with weight stigma: an investigation of overweight and obese adults. Obesity (Silver Spring). 2006;14(10):1802-1815.
  18. Obesity Action Coalition. Understanding obesity stigma brochure. www.obesityaction.org/get-educated/public-resources/brochures-guides/understanding-obesity-stigma-brochure. Accessed August 11, 2020.
  19. Maroney D, Golub S. Nurses' attitudes toward obese persons and certain ethnic groups. Percept Mot Skills. 1992;75(2):387-391.
  20. Alberga AS, Edache IY, Forhan M, Russell-Mayhew S. Weight bias and health care utilization: a scoping review. Prim Health Care Res Dev. 2019;20:e116.
  21. Rubino F, Puhl RM, Cummings DE, et al. Joint international consensus statement for ending stigma of obesity. Nat Med. 2020;26(4):485-497.
  22. Obesity Action Coalition. People-first language. www.obesityaction.org/action-through-advocacy/weight-bias/people-first-language. Accessed September 22, 2020.
  23. Kahan SI. Practical strategies for engaging individuals with obesity in primary care. Mayo Clin Proc. 2018;93(3):351-359.
  24. Canadian Obesity Network. The 5 A’s of obesity management. Practitioner guide. 2011. https://obesitycanada.ca/resources/5as. Accessed August 12, 2020.
  25. Vallis M, Piccinini-Vallis H, Sharma AM, Freedhoff Y. Clinical review: modified 5 As: minimal intervention for obesity counseling in primary care. Can Fam Physician. 2013;59(1):27-31.
  26. Reims K, Ernst D. Using motivational interviewing to promote healthy weight. Fam Pract Manag. 2016;23(5):32-38.
  27. Erlandson M, Ivey LC, Seikel K. Update on office-based strategies for the management of obesity. Am Fam Physician. 2016;94(5):361-368.
  28. Martin KD, Roter DL, Breach MC, Carson KA, Cooper LA. Physician communication behaviors and trust among black and white patients with hypertension. Med Care. 2013;51(2):151-157.
  29. Van Horn L, Carson JA, Appel LJ, et al; American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Stroke Council. Recommended dietary pattern to achieve adherence to the American Heart Association/American College of Cardiology (AHA/ACC) guidelines: a scientific statement from the American Heart Association. Circulation. 2016;134(22):e505-e529.
  30. Bazzano LA, Hu T, Reynolds K, et al. Effects of low-carbohydrate and low-fat diets: a randomized trial. Ann Intern Med. 2014;161(5):309-318.
  31. Unick JL, Beavers D, Jakicic JM, et al; Look AHEAD Research Group. Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial. Diabetes Care. 2011;34(10):2152-2157.
  32. Wing RR, Lang W, Wadden TA, et al; Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481-1486.
  33. Lazo M, Solga SF, Horska A, et al; Fatty Liver Subgroup of the Look AHEAD Research Group. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010;33(10):2156-2163.
  34. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51(1):121-129.
  35. Foster GD, Borradaile KE, Sanders MH, et al; Sleep AHEAD Research Group of Look AHEAD Research Group. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med. 2009;169(17):1619-1626.
  36. Després JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ. 2001;322(7288):716-720.
  37. Department of Health and Human Services. Executive Summary. Physical Activity Guidelines for Americans, 2nd edition. Washington, DC: U.S. Department of Health and Human Services; 2018.
  38. West JH, Belvedere LM, Andreasen R, Frandsen C, Hall PC, Crookston BT. Controlling your "app"etite: how diet and nutrition-related mobile apps lead to behavior change. JMIR Mhealth Uhealth. 2017;5(7):e95.
  39. Middleton KR, Anton SD, Perri MG. Long-term adherence to health behavior change. Am J Lifestyle Med. 2013;7(6):395-404.
  40. Fothergill E, Guo J, Howard L, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity (Silver Spring). 2016;24(8):1612-1619.
  41. Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther. 2014;95(1):53-66.
  42. Mechanick JI, Youdim A, Jones DB, et al; American Association of Clinical Endocrinologists; Obesity Society; American Society for Metabolic & Bariatric Surgery. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity (Silver Spring). 2013;21 Suppl 1(0 1):S1-S27.
  43. American Society for Metabolic and Bariatric Surgery. Benefits of bariatric surgery. https://asmbs.org/patients/benefits-of-bariatric-surgery. Accessed August 12, 2020.
  44. Schauer PR, Bhatt DL, Kirwan JP, et al; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med. 2017;376(7):641-651.
  45. Biertho L, Simon-Hould F, Marceau S, Lebel S, Lescelleur O, Biron S. Current outcomes of laparoscopic duodenal switch. Ann Surg Innov Res. 2016;10:1.
  46. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248-256.
  47. American Society for Metabolic and Bariatric Surgery. Bariatric surgery misconceptions. https://asmbs.org/patients/faqs-of-bariatric-surgery?/patients/bariatric-surgery-misconceptions. Accessed August 12, 2020.
  48. Kim J, Eisenberg D, Azagury D, Rogers A, Campos GM. American Society for Metabolic and Bariatric Surgery position statement on long-term survival benefit after metabolic and bariatric surgery. Surg Obes Relat Dis. 2016;12(3):453-459.
  49. Lupoli R, Lembo E, Saldalamacchia G, Avola CK, Angrisani L, Capaldo B. Bariatric surgery and long-term nutritional issues. World J Diabetes. 2017;8(11):464-474.
  50. Anderson JW, Konz EC, Frederich RC, Wood CL. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr. 2001;74(5):579-584.
  51. Hall KD, Kahan S. Maintenance of lost weight and long-term management of obesity. Med Clin North Am. 2018;102(1):183-197.
  52. Polidori D, Sanghvi A, Seeley RJ, Hall KD. How strongly does appetite counter weight loss? Quantification of the feedback control of human energy intake. Obesity (Silver Spring). 2016;24(11):2289-2295.
  53. Wadden TA, Hollander P, Klein S, et al; NN8022-1923 Investigators. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443-1451.
  54. le Roux CW, Astrup A, Fujioka K, et al; SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399-1409.
  55. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311(1):74-86.
  56. Look AHEAD Research Group, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145-154.
  57. LeBlanc ES, O’Conner E, Whitlock EP, Patnode CD, Kapka T. Effectiveness of primary care–relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155(7):434-447.
  58. Wadden TA, Tronieri JS, Sugimoto D, et al. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial. Obesity (Silver Spring). 2020;28(3):529-536.